Last reviewed · How we verify
NCT05986786: ALVOEYE-D
Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease
Phase 3 trial testing Patients will receive 1 IVT injection of AVT06 PFS depending on their chorioretinal vascular disease schedule in Chorioretinal Vascular Disease in 35 participants. Completed in 21 March 2025.
19 April 2024
Quick facts
| Lead sponsor | Alvotech Swiss AG |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 28 February 2024 |
| Primary completion | 19 April 2024 |
| Estimated completion | 21 March 2025 |
| Sites | 1 location across Georgia |
Drugs / interventions tested
- Patients will receive 1 IVT injection of AVT06 PFS depending on their chorioretinal vascular disease schedule
Conditions studied
- Chorioretinal Vascular Disease — all drugs for Chorioretinal Vascular Disease →
Sponsor
Alvotech Swiss AG — full company profile →
Who can join
18 and older, any sex, with Chorioretinal Vascular Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-arm, open label, multicenter clinical study to evaluate the handling and safety of AVT06 pre-filled syringe (PFS) in subjects with chorioretinal vascular disease followed by an optional extension phase of AVT06 pre-filled syringe (PFS)
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05986786
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Alvotech Swiss AG trials
Trials by the same sponsor.
- NCT06732804 — Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio · Phase 1 · completed
- NCT06570772 — Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio · Phase 3 · terminated
- NCT06400719 — Pilot Study of AVT16 in Healthy Adult Subjects · Phase 1 · completed
- NCT05876949 — AVT03 With Xgeva in Healthy Male Subjects · Phase 1 · completed
- NCT05842213 — Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05986786 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alvotech Swiss AG
- Last refreshed: 22 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05986786.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing